What should I do if the Carpisetin/Tunicade drug fails?

In clinical studies, some patients treated with Capivasertib may experience drug resistance or drug failure. This is mainly related to tumor heterogeneity, AKT pathway activation mode, gene mutation background, and treatment compliance. Drug failure is usually manifested by tumor recurrence, imaging progression, or abnormal elevation of biochemical indicators. In response to this situation, clinical strategies include combination therapy, protocol adjustment, and alternative therapy selection.

First, for patients who have failed monotherapy, doctors may consider using carpisetin in combination with other targeted drugs or endocrine therapy to enhance the inhibitory effect on tumor signaling pathways. Combination therapy can reduce the occurrence of drug resistance through multi-target intervention while improving treatment benefits. For example, in the treatment of breast cancer, carpisetin is often used in combination with aromatase inhibitors or other PI3K/AKT/mTOR pathway inhibitors to deal with tumor progression or drug resistance.

Secondly, when the combined strategy still cannot control the disease, other targeted drugs or chemotherapy regimens can be switched to based on the patient's genetic test results and pathological type. Overseas guidelines suggest that for patients with clear mutations related to the PI3K/AKT pathway, relevant inhibitors may be considered for substitution or included in clinical trials to explore new treatment possibilities. At the same time, the patient's systemic status, tumor markers and imaging changes will be closely monitored clinically to ensure that progress is detected in a timely manner and corresponding intervention measures are taken.

In addition, the patient's own lifestyle, nutritional status, and treatment compliance will also affect drug efficacy. Properly adjusting living habits, maintaining a regular schedule, and regular follow-up and monitoring can delay the occurrence of drug resistance to a certain extent and improve the effectiveness of treatment. In short, drug failure is not the end point of treatment. Scientific management and multi-program strategies can provide patients with new treatment options, maximize survival and maintain quality of life.

Reference materials:https://www.drugs.com/mtm/capivasertib.html